Please assess the completion status of the following clinical trial:

Trial Title: Japanese Study of BMS-901608 (Elotuzumab) in Combination With Lenalidomide and Low Dose Dexamethasone

Study Design Characteristics:
- Allocation: NON_RANDOMIZED
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE1
- Number of Arms: 2.0

Eligibility Criteria:
For additional information, please contact the BMS oncology clinical trial information service at 855-216-0126 or email MyCancerStudyConnect@emergingmed.com. Please visit www.BMSStudyConnect.com for more information on clinical trial participation.~Inclusion Criteria:~* Received between 1 to 4 prior lines of therapy~* Measureable disease~* Men and women of childbearing potential (WOCBP) must be using two acceptable methods of contraception~* Men must agree to use a latex condom and a second form of birth control during sexual contact with WOCBP and must agree to not donate semen during study drug therapy~* Subjects must be willing to refrain from blood donations during study drug therapy~Exclusion Criteria:~* Subjects with non-secretory or oligo-secretory or light-chain only myeloma or active/prior plasma cell leukemia or known /suspect POEMS syndrome~* Solitary bone or solitary extramedullary plasmacytoma as the only evidence of plasma cell dyscrasia~* Unable to take aspirin daily as prophylactic anticoagulation therapy. Prior history of inability to tolerate weekly 40 mg dexamethasone~* History of renal failure~* History of clinical significant thrombosis, such as treatment for thrombosis was required

- Gender: ALL
- Minimum Age: 20 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- BMS-901608 (Elotuzumab) 10mg (Type: EXPERIMENTAL): None
- BMS-901608 (Elotuzumab) 20mg (Type: EXPERIMENTAL): None

Based on this trial design, predict the completion outcome and termination type (if applicable).